Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 4/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | IKBKB | O14920 | 1/20 | 0.59 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | HRH2 | P25021 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL504864 | 1.00 | NAMPT (0.61) | NAMPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| Chs-828 SCHEMBL504892 | 1.00 | NAMPT (0.61) | NAMPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL504126 | 1.00 | NAMPT (0.61) | NAMPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL505053 | 1.00 | NAMPT (0.61) | NAMPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL504863 | 1.00 | NAMPT (0.61) | NAMPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL504982 | 1.00 | NAMPT (0.61) | NAMPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL504997 | 1.00 | NAMPT (0.61) | NAMPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL504983 | 1.00 | NAMPT (0.61) | NAMPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL505054 | 1.00 | NAMPT (0.61) | NAMPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| Chs-828 SCHEMBL504150 | 1.00 | NAMPT (0.61) | NAMPTCYP3A4CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023068423-A1 | COMPLEX ANTICANCER DRUG COMPOSITION USING PHOTOREACTIVITY AND PREPARATION METHOD THEREFOR | 닥터아이앤비(주) | 2023-04-27 | — | — | WO | claimed |
| US-20220125814-A1 | CANCER COMBINATION THERAPIES UTILIZING A NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITOR IN COMBINATION WITH A NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY PRECURSOR | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2022-04-28 | — | — | US | claimed |
| US-20200165608-A1 | INHIBITION OF VASCULAR ENDOTHELIAL CELL-MEDIATED PHAGOCYTIC PROCESSES FOR TREATMENT OF DEMYELINATING CONDITIONS | NATIONAL SCIENCE FOUNDATION | 2020-05-28 | — | — | US | claimed |
| US-8859594-B2 | Polymorphs of N-(6-(4-chlorophenoxy)hexyl)-N′-cyano-N″-(4-pyridyl)guanidine, and preparation thereof and use thereof | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2014-10-14 | — | — | US | claimed |
| US-20130281494-A1 | POLYMORPHS OF N-(6-(4-CHLOROPHENOXY)HEXYL)-N'-CYANO-N\"-(4-PYRIDYL)GUANIDINE, AND PREPARATION THEREOF AND USE THEREOF | TIANJIN MICHELE SCI-TECH DEVELOPMENT CO., LTD. (CN) | 2013-10-24 | — | — | US | claimed |
| EP-2634173-A1 | POLYMORPH OF N-(6-(4-CHLOROPHENOXY)HEXYL)-N'-CYANO-N''-(4-PYRIDYL)GUANIDINE, AND PREPARATION THEREFOR AND USE THEREOF | Tianjin Hemay Bio-Tech Co., Ltd. (CN) | 2013-09-04 | — | — | EP | claimed |
| US-20120029036-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PYRIDYL CYANOGUANIDINE, PROCESS FOR PREPARING THE SAME AND USE THEREOF | TIANJIN MICHELE SCI-TECH DEVELOPMENT CO., LTD. (CN) | 2012-02-02 | — | — | US | claimed |
| EP-2394649-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING PYRIDYL CYANOGUANIDINES, PREPARATION METHODS AND USES THEREOF | Tianjin Hemay Bio-Tech Co., Ltd. (CN) | 2011-12-14 | — | — | EP | claimed |
| EP-1411984-B1 | COMBINATION MEDICAMENT FOR TREATMENT OF NEOPLASTIC DISEASES WHICH CONTAINS CYANOGUANIDINE IKK INHIBITORS AND A SECOND ANTI-NEOPLASTIC DRUG | LEO PHARMA AS (DK) | 2008-05-07 | — | — | EP | claimed |
| EP-1411984-A2 | COMBINATION MEDICAMENT FOR TREATMENT OF NEOPLASTIC DISEASES WHICH CONTAINS CYANOGUANIDINE IKK INHIBITORS AND A SECOND ANTI-NEOPLASTIC DRUG | Leo Pharma A/S (DK) | 2004-04-28 | — | — | EP | claimed |
| US-6642215-B2 | Using cyanoguanidine compound; anticancer agents | LEO PHARMA A/S (DK) | 2003-11-04 | — | — | US | claimed |
| US-20030045515-A1 | Combination medicament for treatment of neoplastic diseases | BINDERUP LISE (DK) | 2003-03-06 | — | — | US | claimed |
| US-20030004192-A1 | Method of modulating NF-kB activity | LEO PHARMA A/S (DK) | 2003-01-02 | — | — | US | claimed |
| WO-2002094265-A1 | A METHOD OF MODULATING NF-$G(K)B ACTIVITY | LEO PHARMA A/S (DK) | 2002-11-28 | — | — | WO | claimed |
| WO-2002094322-A2 | COMBINATION MEDICAMENT FOR TREATMENT OF NEOPLASTIC DISEASES CONTAINING CYANOGUANIDINE IKK INHIBITORS AND A SECOND ANTI-NEOPLASTIC DRUG | LEO PHARMA A/S (DK) | 2002-11-28 | — | — | WO | claimed |
| US-5696140-A | FOR TREATMENT OF ASTHMA, ALLERGIES, NERVOUS SYSTEM DISORDERS OR CANCER | LEO PHARMACEUTICAL PRODUCTS LTD. (DK) | 1997-12-09 | — | — | US | claimed |
| WO-2023068423-A1 | COMPLEX ANTICANCER DRUG COMPOSITION USING PHOTOREACTIVITY AND PREPARATION METHOD THEREFOR | 닥터아이앤비(주) | 2023-04-27 | — | — | WO | disclosed |
| WO-2022104108-A1 | METHODS AND COMPOSITIONS FOR CANCER THERAPY | OHIO STATE INNOVATION FOUNDATION (US) | 2022-05-19 | — | — | WO | disclosed |
| WO-2002042265-A2 | CYANOGUANIDINE PRODRUGS | LEO PHARMA A/S (DK) | 2002-05-30 | — | — | WO | disclosed |
| US-5696140-A | FOR TREATMENT OF ASTHMA, ALLERGIES, NERVOUS SYSTEM DISORDERS OR CANCER | LEO PHARMACEUTICAL PRODUCTS LTD. (DK) | 1997-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045515-A1 | Combination medicament for treatment of neoplastic diseases | CHUK, IKBKB, IKBKE | NAMPT 4332/4885CYP3A4 3014/4885CYP2D6 2769/4885 |
| US-20030004192-A1 | Method of modulating NF-kB activity | IKBKB, NFKBIA, NFKB2 | NAMPT 4372/4885CYP3A4 3181/4885CYP2D6 2881/4885 |
| US-20130281494-A1 | POLYMORPHS OF N-(6-(4-CHLOROPHENOXY)HEXYL)-N'-CYANO-N\"-(4-PYRIDYL)GUANIDINE, AND PREPARATION THEREOF AND USE THEREOF | PNP, HCCS, UNG | NAMPT 289/4885CYP3A4 232/4885CYP2D6 184/4885 |
| US-20120029036-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PYRIDYL CYANOGUANIDINE, PROCESS FOR PREPARING THE SAME AND USE THEREOF | PLPBP, PYGL, QDPR | NAMPT 511/4885CYP3A4 117/4885CYP2D6 101/4885 |
| US-20220125814-A1 | CANCER COMBINATION THERAPIES UTILIZING A NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITOR IN COMBINATION WITH A NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY PRECURSOR | NAMPT, NADK, NNT | NAMPT 1/4885CYP3A4 3656/4885CYP2D6 4289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.